Small size Drug Conjugates against solid tumors with new therapeutic window
Affilogic is developing an OncoFitin-Drug-Conjugate: anti-Mesothelin Nanofitin®-MMAE conjugate
The very rapid diffusion of the Nanofitins® within the whole tumor due to their small size represents a core advantage over other vectoring agents, as it can deliver cytotoxic payloads on a more targeted manner.
Notably, this size also allows non-engaged Nanofitins® to be rapidly cleared, highly reducing side effects observed with other vectoring solutions such as “on target off tumor”.
Our current ODC program on delivery of MMAE to Mesothelin positive tumors is capitalizing upon our previous work with anti-EGFR Nanofitins, showing very attractive in vivo results, with the capacity to significantly impair EGFR positive tumor growth in mice.
Satellite projects :
EGFR Targeting drug conjugate : Affilogic previously worked on developing EGFR targeting Nanofitins to deliver MMAE to EGFR positive tumors. The high scaffold stability and the absence of cysteine allows regio-selective conjugation to MMAE with a very good yield. In-vivo data of anti-EGFR Nanofitin-Drug-Conjugates demonstrated EGFR positive tumor growth inhibition in xenograft mice (Huet et al., Targeted Nanofitin-drug Conjugates Achieve Efficient Tumor Delivery and Therapeutic Effect in an EGFRpos Mouse Xenograft Model, Mol Cancer Ther (2023))